The relationship between lung cancer histology and the clinicopathological characteristics of bone metastases

被引:39
|
作者
dos Reis Oliveira, Marcelo Braganca [1 ]
de Queiroz Mello, Fernanda Carvalho [2 ,3 ]
Machado Paschoal, Marcos Eduardo [3 ]
机构
[1] Univ Fed Rio de Janeiro, Trauma Orthopaed Serv, Rio De Janeiro, Brazil
[2] Univ Fed Rio de Janeiro, Fac Med, Rio De Janeiro, Brazil
[3] Univ Fed Rio de Janeiro, Thorac Dis Inst, Rio De Janeiro, Brazil
关键词
Lung cancer; Bone metastasis; SRE; Histology; SKELETAL-RELATED EVENTS; ZOLEDRONIC ACID; PROGNOSTIC-FACTORS; SOLID TUMORS; DOUBLE-BLIND; PHASE-III; SURVIVAL; EPIDEMIOLOGY; PREDICTORS; PLACEBO;
D O I
10.1016/j.lungcan.2016.03.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Lung cancer is the leading cause of death due to cancer, and bone is one of the most frequent sites of metastasis. However, there is no published evidence regarding an association between lung cancer histology and skeletal complications. Therefore, we evaluated the influence of lung cancer histology on the frequency of bone metastases (BMs), skeletal-related events (SREs), and survival after BM. Material and methods: This retrospective study evaluated medical records from 413 patients who were diagnosed with lung cancer between 2003 and 2012. The prevalences of BMs and SREs were calculated, and their associations with the histological subtypes were evaluated using the chi-square test, odds ratios (OR), and 95% confidence intervals (CI). Overall survivals and associations with the histological subtypes were evaluated using the Kaplan-Meier method and the log-rank test. Results: The prevalences of BM, synchronous BM, and SREs were 28.2%, 70.4%, and 68.7%, respectively. Adenocarcinoma was the most common histological subtype (46.7%), and was significantly more frequent among patients with BM (58.3% vs. 42.1%; p = 0.003; OR: 1.92; 95% CI: 1.29-2.97). Squamous cell was significantly less frequent among patients with BM (13.0% vs. 29.8%; p = 0.0004; OR: 0.35; 95% CI: 0.19-0.64). The median survival time after the first BM diagnosis was 4 months, and there was no significant difference in the survival periods for the various histological subtypes. Conclusion: Adenocarcinoma and squamous cell were significantly associated with higher and lower risks of developing BM, respectively. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:19 / 24
页数:6
相关论文
共 50 条
  • [1] The incidence and clinical impact of bone metastases in non-small cell lung cancer
    Kuchuk, Michael
    Kuchuk, Iryna
    Sabri, Elham
    Hutton, Brian
    Clemons, Mark
    Wheatley-Price, Paul
    LUNG CANCER, 2015, 89 (02) : 197 - 202
  • [2] Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non-Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases
    Tam, Andrew H.
    Schepers, Allison J.
    Qin, Angel
    Nachar, Victoria R.
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (06) : 697 - 704
  • [3] Zoledronic acid in lung cancer with bone metastases: a review
    Isla, Dolores
    Afonso, Ruth
    Bosch-Barrera, Joaquim
    Martinez, Natividad
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (04) : 421 - 426
  • [4] Prevention and Management of Bone Metastases in Lung Cancer A Review
    Al Husaini, Hamed
    Wheatley-Price, Paid
    Clemons, Mark
    Shepherd, Frances A.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (02) : 251 - 259
  • [5] Incidence and consequences of bone metastases in lung cancer patients
    Kuchuk, Michael
    Addison, Christina L.
    Clemons, Mark
    Kuchuk, Iryna
    Wheatley-Price, Paul
    JOURNAL OF BONE ONCOLOGY, 2013, 2 (01) : 22 - 29
  • [6] The Association between Fever and Prognosis in Lung Cancer Patients with Bone Metastases Receiving Zoledronic Acid
    Sunaga, Tomiko
    Shimamoto, Kazushi
    Nakamura, Shoko
    Takahashi, Noriko
    Higashino, Mayumi
    Hozumi, Tomomi
    Matsui, Mitsuki
    Nagatani, Akiko
    Kokubu, Fumio
    Kogo, Mari
    Sasaki, Tadanori
    CHEMOTHERAPY, 2017, 62 (06) : 327 - 333
  • [7] Epidemiology, management and cost of bone metastases from lung cancer
    Decroisette, C.
    Galerneau, L. -M.
    Hominal, S.
    Chouaid, C.
    REVUE DES MALADIES RESPIRATOIRES, 2013, 30 (04) : 309 - 315
  • [8] Bisphosphonate Use in Patients with Lung Cancer and Bone Metastases Recommendations of a European Expert Panel
    De Marinis, Filippo
    Eberhardt, Wilfried
    Harper, Peter G.
    Massuti Sureda, Bartomeu
    Nackaerts, Kristiaan
    Soerensen, Jens Benn
    Syrigos, Kostas
    Tredaniel, Jean
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (10) : 1280 - 1288
  • [9] Bone Metastases and Non-Small Cell Lung Cancer: From Bisphosfonates to Targeted Therapy
    Rossi, A.
    Gridelli, C.
    Ricciardi, S.
    de Marinis, F.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (32) : 5524 - 5535
  • [10] Relationship between morphine and radiotherapy for management of symptomatic bone metastases from lung cancer
    Hiromichi Ishiyama
    Akiko Shibata
    Keiji Niino
    Takaaki Hosoya
    Supportive Care in Cancer, 2004, 12 : 743 - 745